PEG |
Gene delivery |
Polyethylenimine(PEI)-PEG |
cDNA of herpes simplex virus thymidine kinase gene (HSVtk) and granulocyte–macrophage colony-stimulating factor (GM-CSF) |
N.D. |
[21] |
Tumor targeting |
octreotide(Phe)-PEG |
Paclitaxel |
|
[22] |
Improved stability and intracellular drug release |
methoxy PEG-b-(poly(2-(diisopropylamino) ethyl methacrylate-co-aminopropyl methacrylamide) (PEDPA) |
Cis-aconityl-doxorubicin |
|
[23] |
Tumor targeting |
PEG |
Fusion toxin consisting of the anti-EpCAM DARPin Ec1 and a domain I-deleted variant of ETA (ETA″) |
rhinovirus 3C model protease—cleavage linker |
[24] |
Drug delivery |
3,3′-dithiodipropionic acid functionalized PEG-b-poly(l-lysine) (mPEG-b-P(LL-DTPA)) |
Paclitaxel |
Disulfide |
[25] |
Multidrug resistance |
D-α-tocopherol PEG succinate (TPGS) |
Paclitaxel |
Disulfide |
[26] |
Improved the therapeutic efficacy |
β-CD, PEG |
Doxorubicin |
hydrazone |
[27] |
Tumor targeting |
PEG |
Paclitaxel |
|
[28] |
Multidrug resistance |
PEG-poly(d,l-lactide) |
4-(N)-stearoyl Gemcitabine |
|
[29] |
Theranosis |
PEG-polylactic acid (PEG-PLA) l |
Dicyanomethylene-4H-pyran-S-CPT |
Disulfide |
[30] |
Tumor targeting |
PEG monomethyl ether (mPEG) |
Artesunate |
Ester |
[31] |
Tumor targeting |
PEG monomethyl ether |
Camptothecin |
Disulfide |
[32] |
Tumor targeting |
PEG |
Camptothecin |
Disulfide |
[33] |
Tumor targeting |
PEG2000 |
Paclitaxel |
MMP2-cleavable linker |
[34] |
Nanogel |
PLGA-PEG-PLGA |
PEGylated Taxol |
|
[35] |
Drug delivery |
mPEG-b-P(ATMC-co-DTC) |
Doxorubicin |
Hydrazone |
[36] |
HPMA |
improving anticancer therapy |
(mPEG5000-b-p(HPMAmLac2-r-AzEMA) |
Doxorubicin-glucuronide prodrug (DOX-propGA3) |
Glucuronide (β-glucuronidase cleavable linker) |
[37] |
Prevent metastasis |
HPMA copolymer |
E-selectin binding peptide (Esbp)-doxorubicinor (KLAKLAK)2
|
|
[38] |
Drug delivery |
HPMA copolymer |
H1-S6A, F8A peptide |
GFLG (Cathepsin cleavage linker) |
[39] |
Tumor targeting |
HPMA copolymer |
Doxorubicin |
GFLG and MMP cleavable linker |
[40] |
Improved the therapeutic efficacy |
HPMA copolymer |
Doxorubicin, 5-FU |
Hydrazone, GFLG |
[41] |
Theranosis |
Star polymer: poly(amido amine) (PAMAM) dendrimers and HPMA |
Doxorubicin or TAMRA fluorescent dye |
Hydrazone |
[42] |
Improved Bioavailability |
Star polymer: poly(amido amine) (PAMAM) dendrimers and HPMA |
Pirarubicin |
Hydrazone |
[43,44] |
Drug delivery |
HPMA copolymer |
Iodine-125 |
Hydrazone |
[45] |
Drug delivery |
HPMA copolymer |
Paclitaxel, Gemcitabine |
GFLG |
[46] |
Drug delivery |
Starch + HPMA copolymer |
Camptothecin |
|
[47] |
Gene delivery |
galactosylated 2-hydroxypropylmethacrylamide-s-3-guanidinopropyl methacrylamide (HPMAs–GPMA) |
shRNA |
|
[48] |
Drug delivery |
HPMA |
Indium-111, Yttrium-90 |
|
[49] |
Improved the therapeutic efficacy |
multiblock poly HPMA |
Gemcitabine, Paclitaxel and Doxorubicin |
GFLG |
[50] |
Theranosis |
HPMA copolymer |
Zinc protoporphyrin |
|
[16,51] |
SMA |
Photodynamic therapy |
SMA |
Zinc protoporphyrin |
Amide |
[52] |
PLGA |
Improved Bioavailability |
PLGA |
Gemcitabine |
Amide |
[53] |
PGG |
Improved Bioavailability |
PGG |
Paclitaxel |
Glutamic acid |
[54,55] |